| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/AJG.2017.170 |
| P698 | PubMed publication ID | 28585556 |
| P50 | author | Christopher D Stave | Q56234820 |
| George Cholankeril | Q59749426 | ||
| Colin W Howden | Q87752670 | ||
| Sanjaya K Satapathy | Q88155709 | ||
| Satheesh Nair | Q88834367 | ||
| Faisal Kamal | Q89635985 | ||
| Aijaz Ahmed | Q47168895 | ||
| P2093 | author name string | Muhammad Ali Khan | |
| Sehrish Kamal | |||
| Ankur Seth | |||
| Utkarsh Singh | |||
| Deepansh Gupta | |||
| P2860 | cites work | The state of US health, 1990-2010: burden of diseases, injuries, and risk factors | Q23909354 |
| Full publication of results initially presented in abstracts | Q24245597 | ||
| Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase | Q24645348 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | Q27860581 | ||
| Coronary artery disease in patients with liver cirrhosis. | Q51430413 | ||
| Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats | Q59123185 | ||
| Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation | Q79861314 | ||
| Natural history of hepatitis C | Q80384219 | ||
| Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats | Q84789545 | ||
| Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial | Q86035302 | ||
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) | Q28345499 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids | Q29620653 | ||
| Statins in liver disease: a molehill, an iceberg, or neither? | Q30446668 | ||
| Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma | Q33765060 | ||
| Clinical outcomes of compensated and decompensated cirrhosis: A long term study | Q33948229 | ||
| Quality of nonstructured and structured abstracts of original research articles in the British Medical Journal, the Canadian Medical Association Journal and the Journal of the American Medical Association | Q34276731 | ||
| Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies | Q34468844 | ||
| Statin use in patients with cirrhosis: a retrospective cohort study | Q34661975 | ||
| Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C | Q34747195 | ||
| Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions | Q35136411 | ||
| Hepatotoxicity of hypolipidemic drugs | Q35184569 | ||
| KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation | Q36399199 | ||
| Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. | Q36505496 | ||
| Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. | Q36845502 | ||
| Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. | Q37029796 | ||
| Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients | Q37385419 | ||
| EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy | Q37609988 | ||
| Anti-fibrogenic strategies and the regression of fibrosis | Q37865870 | ||
| Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis | Q38051955 | ||
| Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study | Q38831540 | ||
| Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis | Q40100867 | ||
| Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals | Q40501796 | ||
| Statin drugs decrease progression to cirrhosis in HIV/HCV co-infected individuals | Q40588764 | ||
| Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. | Q40699088 | ||
| Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection | Q40713539 | ||
| Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. | Q41109284 | ||
| Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development | Q42168234 | ||
| Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis | Q42467738 | ||
| Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians | Q43001285 | ||
| Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C | Q43991768 | ||
| Effects and regulation of connective tissue growth factor on hepatic stellate cells. | Q44028827 | ||
| Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. | Q44779682 | ||
| Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study | Q45811781 | ||
| Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial | Q46126097 | ||
| The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins | Q46188566 | ||
| Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells | Q46618533 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| chronic liver disease | Q5113984 | ||
| decompensated cirrhosis | Q109887496 | ||
| P304 | page(s) | 1495-1505 | |
| P577 | publication date | 2017-06-06 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis | |
| P478 | volume | 112 |
| Q57465017 | Asprin and statin use for management of atherosclerotic cardiovascular disease in liver transplant candidates: Are we missing the mark? |
| Q91756003 | Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes |
| Q92931544 | Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial |
| Q92330882 | Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis |
| Q64093529 | Current and future pharmacological therapies for managing cirrhosis and its complications |
| Q52663547 | Dos and Don'ts in the Management of Cirrhosis: A View from the 21st Century. |
| Q46131886 | Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression? |
| Q90622879 | Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease |
| Q48363108 | Letter: statins and cirrhosis |
| Q58555748 | Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis |
| Q93004228 | Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease |
| Q88914388 | Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes |
| Q55043848 | Semen Brassicae ameliorates hepatic fibrosis by regulating transforming growth factor-β1/Smad, nuclear factor-κB, and AKT signaling pathways in rats. |
| Q64095245 | Statin use in cirrhotic patients with infectious diseases: A population-based study |
| Q64284712 | Targeting angiogenesis in Duchenne muscular dystrophy |
| Q64081318 | The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease |
| Q58584433 | The Mevalonate Pathway Is Indispensable for Adipocyte Survival |
| Q90420440 | Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis |
Search more.